![Day One Biopharmaceuticals announces a new ex-U.S. licensing agreement with Ipsen to commercialize tovorafenib](https://oncodaily.com/pub/uploads/2024/07/4c3300ddc2a848a5b93f91877ebf2561.jpg)
Photo from Day One Biopharmaceuticals/LinkedIn
Jul 27, 2024, 22:01
Day One Biopharmaceuticals announces a new ex-U.S. licensing agreement with Ipsen to commercialize tovorafenib
Day One Biopharmaceuticals shared a post on LinkedIn:
”We are pleased to announce a new ex-U.S. licensing agreement with Ipsen to commercialize tovorafenib. This collaboration highlights our shared commitment to bring novel therapeutics to patients worldwide who have limited treatment options. Learn more.”